Safety and Tolerability of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist BAY 94-8862 in Patients With Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease: A Randomized, Double-Blind Trial

Study Questions:

What is the safety and tolerability of BAY 94-8862, a next-generation nonsteroidal mineralocorticoid receptor antagonist (MRA) with improved selectivity for the mineralocorticoid receptor (MR) over other steroid hormone receptor, compared with spironolactone 25-50 mg/day, in patients with chronic heart failure (HF) and a reduced left ventricular ejection fraction (HFrEF) with New York Heart Association class II-III symptoms and mild to moderate chronic kidney disease (CKD)?